首页> Cancer letters> Combined blockade of polo-like kinase and pan-RAF is effective against NRAS-mutant non-small cell lung cancer cells.

Combined blockade of polo-like kinase and pan-RAF is effective against NRAS-mutant non-small cell lung cancer cells.

导出 LinkOut

翻译打印收藏纠错

第一作者： Siyeon,Park

第一单位： Seoul National University Cancer Research Institute, South Korea.

作者： Siyeon,Park ^[1] ; Tae Min,Kim ^[2] ; Sung-Yup,Cho ^[3] ; Soyeon,Kim ^[4] ; Yumi,Oh ^[5] ; Miso,Kim ^[6] ; Bhumsuk,Keam ^[6] ; Dong-Wan,Kim ^[6] ; Dae Seog,Heo ^[6]

作者单位： Seoul National University Cancer Research Institute, South Korea. ^[1] Seoul National University Cancer Research Institute, South Korea; Department of Internal Medicine, Seoul National University Hospital, South Korea. Electronic address: gabriel9@snu.ac.kr. ^[2] Seoul National University Cancer Research Institute, South Korea; Department of Biochemistry and Molecular Biology, Seoul National University College of Medicine, South Korea; Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, South Korea. Electronic address: csybio@snu.ac.kr. ^[3] Seoul National University Cancer Research Institute, South Korea; Biomedical Research Institute, Seoul National University Hospital, Seoul, South Korea. ^[4] Department of Biochemistry and Molecular Biology, Seoul National University College of Medicine, South Korea. ^[5] Seoul National University Cancer Research Institute, South Korea; Department of Internal Medicine, Seoul National University Hospital, South Korea. ^[6]

关键词 High-throughput screening NRAS-mutant lung cancer PLK1 inhibitor Pan-RAF inhibitor